Therapeutic potential of TGF-β inhibition in chronic renal failure

Elena Gagliardini, Ariela Benigni

Research output: Contribution to journalArticlepeer-review


Chronic kidney diseases are emerging as a worldwide public health problem. The progression of kidney diseases closely correlates with the accumulation of extracellular matrix leading to glomerulosclerosis and tubulointerstitial injury. Transforming growth factor (TGF)-β has been identified as a key mediator of kidney matrix accumulation. Overexpression of TGF-β isoforms and their receptors was observed in a variety of renal diseases in both animals and humans. Given its crucial role in fibrotic kidney disease, TGF-β has been recently considered as a possible target in the management of chronic renal diseases. This review discusses the role of TGF-β in renal fibrosis and provides an overview of the strategies that, when interfering with TGF-β expression and signalling, could be employed as new renoprotective treatments.

Original languageEnglish
Pages (from-to)293-304
Number of pages12
JournalExpert Opinion on Biological Therapy
Issue number3
Publication statusPublished - Mar 2007


  • Progressive nephropathies
  • Proteinuria
  • Renal fibrosis
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology


Dive into the research topics of 'Therapeutic potential of TGF-β inhibition in chronic renal failure'. Together they form a unique fingerprint.

Cite this